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The triggering receptor expressed in
myeloid/microglial cells 2 (TREM2;
encoded at chr6p21.1) is a glycosylated
type 1 transmembrane sensor-receptor
of the immunoglobulin-lectin-like gene
superfamily expressed in the human
central nervous system (CNS). TREM2
normally functions in immune surveil-
lance, sensing and phagocytosis, including
the homeostatic clearance of deleterious
extracellular debris. Perhaps not too sur-
prising, TREM2 deficiencies have been
associated with pathological deficits in
phagocytosis, amyloidogenesis and a
compromised innate immune system in
the inflammatory, neuro-degenerative
illnesses polycystic lipomembranous
osteodysplasia with sclerosing leukoen-
cephalopathy (PLOSL) and more recently
with late onset Alzheimer’s disease (AD;
Forabosco et al., 2013; Golde et al., 2013;
Guerreiro et al., 2013; Jonsson et al.,
2013; Neumann and Daly, 2013; Zhao
et al., 2013). Meta-analysis from mul-
tiple genome-wide association studies
(GWAS) in AD have recently identified
an rs75932628 (R47H; loss of function)
variant in TREM2 as a strong AD risk fac-
tor, conveying an increase in AD with an
odds ratio of 1.3–8.8-fold (p = 0.0076) in
recent studies, an effect size comparable
to that of the APOEe4 allele (Gonzalez
Murcia et al., 2013). However, TREM2
R47H mutations appear to be relatively
rare in the human populations so far
studied (Gonzalez Murcia et al., 2013;
Guerreiro et al., 2013; Hampel and Lista,
2013; Jonsson et al., 2013; Lattante et al.,
2013).
Not so rare in AD, however, are sig-
nificant focal increases in the abundance
of a pro-inflammatory, NF-κB-regulated
miRNA-34a (encoded at chr1p36.22) in
virtually all AD cells and tissues examined
compared to age-matched controls, as well
as in amyloid overexpressing transgenic
murine models for AD (Schipper et al.,
2007; Wang et al., 2009; Zhao et al., 2013).
For example, miRNA-34a was recently
shown to be up-regulated, and TREM2
was found to be significantly down-
regulated, in short post-mortem inter-
val (mean ∼2 h) samples of sporadic
AD hippocampal CA1 compared with
age-matched controls. This novel epige-
netic mechanism appears to be medi-
ated by virtue of an unusually strong
miRNA-34a recognition feature within
the 299 nucleotide TREM2 mRNA 3′-
untranslated (3′-UTR) region (energy of
association, EA ≤ 16 kcal/mol; Figure 1)
(Zhao et al., 2013). The stress- and
inflammation-induced transcription fac-
tor NF-κB, a driver for miRNA-34a expres-
sion, is also strongly up-regulated in
the hippocampal CA1, and both NF-
κB inhibitors and stabilized anti-miRNA-
34a are effective in restoring TREM2
back to homeostatic levels (Kaltschmidt
and Kaltschmidt, 2009; Lukiw, 2013;
Zhao et al., 2013). Interestingly, a patho-
logically up-regulated miRNA-34a has
been strongly associated with progres-
sive neurotrophic deficits (Wang et al.,
2009), altered synaptogenesis (Agostini
et al., 2011) and deficient immune and
phagocytotic responses in inflammatory
degenerative disorders such as cardiovas-
cular disease (Boon et al., 2013), multi-
ple sclerosis (Junker et al., 2009), and in
sporadic AD mononuclear cells (Schipper
et al., 2007) as well as in AD brain (Zhao
et al., 2013).
Abundant evidence indicates that mul-
tiple genes, through multiple genetic
processes, initiate and propagate AD-
type change. Collectively, emerging
observations indicate that an epigenetic
mechanism involving anNF-κB-mediated,
miRNA-34a-regulated down-regulation
of TREM2 expression may shape innate
immunity, inflammation and the extinc-
tion of the phagocytic response that
contributes to amyloidogenesis and
inflammatory neurodegeneration. Pro-
inflammatory transcription factors and
miRNAs, such as NF-κB and miRNA-
34a, and their target mRNA 3′-UTRs
appear to form a highly interwoven genetic
regulatory network that may escape clas-
sical GWAS- and SNP-based detection.
Interestingly, AD-relevant stress-mediated
up-regulation of miRNA-34a in cul-
tured microglial cells, subsequent
down-regulation in the expression of
TREM2-3′-UTR reporter vectors, and
rescue by stabilized anti-miRNA-34a indi-
cates that this type of pathogenic signaling
can be effectively quenched, at least in vitro
(Lukiw, 2013; Zhao et al., 2013). Totally
novel anti-miRNA strategies involving
miRNA-34a mimics (i.e., MRX34) that
normally induce senescence and apoptosis,
and utilizing liposome delivery technolo-
gies are just now appearing in the clinic
for the treatment of metastatic liver cancer
(Bouchie, 2013). In the near future these
approaches may have considerable poten-
tial in also directing novel, combinatorial
anti-NF-κB- and/or anti-miRNA-based
AD therapeutic strategies that target the
multiple pathogenic pathways which lie at
the core of the AD process.
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FIGURE 1 | A hsa-miRNA-34a-TREM2-mRNA-3′-UTR complementarity map; gene products on
two independent chromosomes orchestrate a down-regulation of TREM2 and a progressive
deficit in cellular debris sensing, phagocytosis and clearance in human neurodegenerative
disease. (A) an NF-κB-sensitive miRNA-34a (encoded at chr1p36.22) and up-regulated in AD has
been found to target (B) the central domain of the 299 nucleotide human TREM2 mRNA
3′-untranslated region (3′-UTR) of the TREM2 gene (C) encoded at chr6p21.1; thus the functional
interaction of 2 independent gene products may be responsible for TREM2 deficits in sporadic AD;
in (B) the miRNA-34a seed sequence 3′-UGUGACGG-5′ is highlighted in yellow; the
complementary TREM2-3′-UTR recognition sequence 5′-ACACTGCT-3′ is highlighted in red; an “|”
indicates a full hydrogen bond between miRNA-34a and the TREM2-mRNA-30-UTR and a “:”
indicates a partial hydrogen bond; the hsa-miRNA-34a recognition feature is located about midway
in the TREM2 mRNA-3′-UTR; other miRNA recognition features located within the TREM2-3′-UTR
may also affect TREM2 mRNA stability and regulate its expression; other miRNA-mRNA pairings
may also be involved in TREM-2 function; the TREM2 gene has no strong NF-κB binding site within
at least 11 kb of its transcription start site (Zhao et al., 2013 and unpublished observations);
ribonucleotide sequences and alignment derived using miRBASE algorithms (European
Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton UK; http://www.ebi.ac.uk/
enright-srv/microcosm/cgi-bin/targets/v5/detailview.pl?transcript _id=ENST00000373113; Lukiw, 2013;
Neumann and Daly, 2013; Zhao et al., 2013).
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